<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38934345</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2574-173X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Neuropsychopharmacology reports</Title><ISOAbbreviation>Neuropsychopharmacol Rep</ISOAbbreviation></Journal><ArticleTitle>Successful treatment with guanfacine in a long-COVID case manifesting marked cognitive impairment.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/npr2.12466</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persistent cognitive impairment is a serious consequence of the post-COVID condition. However, there have been no established effective treatments for this pathophysiology supported by sufficient evidence.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 32-year-old woman became aware of difficulty in word recalling, reading, and writing as well as difficulty in completing various household multitasks 3&#x2009;weeks after the COVID-19 infection. Although blood tests, magnetic resonance imaging, electroencephalography, and Kohs block design test were all within normal limits, completion time by trail making test (TMT) A or B was markedly delayed. Finally, she was referred to our hospital 3&#x2009;months after the infection. At baseline, the THINC integrated tool (THINC-it), a digital battery consisting of the five-item version of the perceived deficit questionnaire (PDQ-5), choice reaction time (CRT), 1-back test, digit symbol substitution test (DSST), and TMT-B, revealed poor capability in attention, working memory, and executive function. Also, near-infrared spectroscopy (NIRS) demonstrated no activation in frontal or temporal regions during verbal fluency task. Extended-release guanfacine (GXR) 2&#x2009;mg/day was initiated and a month later was elevated up to 4&#x2009;mg/day as a maintenance dose. The PDQ-5, CRT, 1-back test, DSST, and TMT-B were dramatically improved 1&#x2009;month after GXR treatment. NIRS finding was also normalized after 2&#x2009;months of treatment. These effects were successfully maintained throughout the 6-month follow-up period.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">GXR may be helpful in improving subjective/objective cognitive functioning and frontotemporal brain activity in long-COVID patients manifesting apparent cognitive impairment.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley &amp; Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8592-6288</Identifier><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higa</LastName><ForeName>Riki</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shiseikai Heiwa Hospital, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuniba</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Technology, University of the Ryukyus Hospital, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinzato</LastName><ForeName>Hotaka</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-0354-1801</Identifier><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takaesu</LastName><ForeName>Yoshikazu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9169-3249</Identifier><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychopharmacol Rep</MedlineTA><NlmUniqueID>101719700</NlmUniqueID><ISSNLinking>2574-173X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">THINC integrated tool</Keyword><Keyword MajorTopicYN="N">cognitive impairment</Keyword><Keyword MajorTopicYN="N">guanfacine</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">near&#x2010;infrared spectroscopy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38934345</ArticleId><ArticleId IdType="doi">10.1002/npr2.12466</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hampshire A, Trender W, Chamberlain SR, Jolly AE, Grant JE, Patrick F, et&#xa0;al. Cognitive deficits in people who have recovered from COVID&#x2010;19. EClinicalMedicine. 2021;39:101044. https://doi.org/10.1016/j.eclinm.2021.101044</Citation></Reference><Reference><Citation>Hellmuth J, Barnett TA, Asken BM, Kelly JD, Torres L, Stephens ML, et&#xa0;al. Persistent COVID&#x2010;19&#x2010;associated neurocognitive symptoms in non&#x2010;hospitalized patients. J Neurovirol. 2021;27:191&#x2013;195. https://doi.org/10.1007/s13365&#x2010;021&#x2010;00954&#x2010;4</Citation></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et&#xa0;al. Persistent neurologic symptoms and cognitive dysfunction in non&#x2010;hospitalized Covid&#x2010;19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol. 2021;8(5):1073&#x2013;1085. https://doi.org/10.1002/acn3.51350</Citation></Reference><Reference><Citation>Aghajani MM. Brain fog: a narrative review of the most common mysterious cognitive disorder in COVID&#x2010;19. Mol Neurobiol. 2023. Online ahead of print. https://doi.org/10.1007/s12035&#x2010;023&#x2010;03715&#x2010;y</Citation></Reference><Reference><Citation>Tziolos N&#x2010;R, Ioannou P, Baliou S, Kofteridis DP. Long COVID&#x2010;19 pathophysiology: what do we know so far? Microorganisms. 2023;11(10):2458. https://doi.org/10.3390/microorganisms11102458</Citation></Reference><Reference><Citation>Fesharaki&#x2010;Zadeh A, Lowe N, Arnsten AFT. Clinical experience with the &#x3b1;2A&#x2010;adrenoceptor agonist, guanfacine, and N&#x2010;acetylcysteine for the treatment of cognitive deficits in &#x201c;long&#x2010;COVID19&#x201d;. Neuroimmunol Rep. 2023;3:100154. https://doi.org/10.1016/j.nerep.2022.100154</Citation></Reference><Reference><Citation>Monastero R, Baschi R. Persistent cognitive dysfunction in a non&#x2010;hospitalized COVID&#x2010;19 long&#x2010;hailer patient responding to cognitive rehabilitation and citicoline treatment. Brain Sci. 2023;13(9):1275. https://doi.org/10.3390/brainsci13091275</Citation></Reference><Reference><Citation>Secades JJ, Gareri P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(s05):S1&#x2013;S89. https://doi.org/10.33588/rn.75S05.2022311</Citation></Reference><Reference><Citation>Arnsten AFT, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012;85(1):45&#x2013;58.</Citation></Reference><Reference><Citation>Hoang K, Watt H, Golemme M, Perry RJ, Ritchie C, Wilson D, et&#xa0;al. Noradrenergic add&#x2010;on therapy with extended&#x2010;release guanfacine in Alzheimer's disease (NorAD): study protocol for a randomized clinical trial and COVID&#x2010;19 amendments. Trials. 2022;23(1):623. https://doi.org/10.1186/s13063&#x2010;022&#x2010;06190&#x2010;3</Citation></Reference><Reference><Citation>McIntyre RS, Best MW, Bowie CR, Carmona NE, Cha DS, Lee Y, et&#xa0;al. The THINC&#x2010;integrated tool (THINC&#x2010;it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry. 2017;78(7):873&#x2013;881. https://doi.org/10.4088/JCP.16m11329</Citation></Reference><Reference><Citation>Dalby M, Annas P, 23andMe Research Team, Harrison JE. Further validation of the THINC&#x2010;it tool and extension of normative data set in a study of n&#x2009;=&#x2009;10.019 typical controls. Int J Methods Psychiatr Res. 2022;31(4):e1922. https://doi.org/10.1002/mpr.1922</Citation></Reference><Reference><Citation>Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestation of COVID&#x2010;19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg. 2020;194:105921. https://doi.org/10.1016/j.clineuro.2020.105921</Citation></Reference><Reference><Citation>Miyazato Y, Tsuzuki S, Morioka S, Terada M, Kutsuna S, Saito S, et&#xa0;al. Factors associated with development and persistence of post&#x2010;COVID conditions: a cross&#x2010;sectional study. J Infect Chemother. 2022;28(9):1242&#x2013;1248. https://doi.org/10.1016/j.jiac.2022.04.025</Citation></Reference><Reference><Citation>Takizawa R, Fukuda M, Kawasaki S, Kasai K, Mimura M, Pu S, et&#xa0;al. Neuroimaging&#x2010;aided differential diagnosis of the depressive state. NeuroImage. 2014;85:498&#x2013;507. https://doi.org/10.1016/j.neuroimage.2013.05.126</Citation></Reference><Reference><Citation>Satomura Y, Sakakibara E, Takizawa R, Koike S, Nishimura Y, Sakurada H, et&#xa0;al. Severity&#x2010;dependent and &#x2010;independent brain regions of major depressive disorder: a long&#x2010;term longitudinal near&#x2010;infrared spectroscopy study. J Affect Disord. 2019;243:249&#x2013;254. https://doi.org/10.1016/j.jad.2018.09.029</Citation></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long&#x2010;COVID. Trends Immunol. 2022;43(4):268&#x2013;270. https://doi.org/10.1016/j.it.2022.02.008</Citation></Reference><Reference><Citation>Arnsten AFT. Guanfacine's mechanism of action in treating prefrontal cortical disorders: successful translation across species. Neurobiol Learn Mem. 2020;176:107327. https://doi.org/10.1016/j.nlm.2020.107327</Citation></Reference><Reference><Citation>Arnsten AF, Ishizawa Y, Xie Z. Scientific rationale for the use of &#x3b1;2A&#x2010;adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023; 28:4540&#x2013;4552. https://doi.org/10.1038/s41380&#x2010;023&#x2010;02057&#x2010;4</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>